T2653 |
SB1317
|
1204918-72-8
|
100%
|
|
SB1317 (TG02) is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
|
T16995 |
TAS05567
|
1429038-15-2
|
98%
|
|
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
|
T12610L |
3-Hydroxy Midostaurin
|
179237-49-1
|
98%
|
|
3-Hydroxy Midostaurin (CGP 52421), a PKC412 metabolite, inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC50 values of roughly 132 nM in cult...
|
T11731 |
JTV-519 free base
|
145903-06-6
|
98%
|
|
JTV-519 free base (K201 free base), recognized for its antiarrhythmic and cardioprotective properties, functions as a Ca2+-dependent blocker of sarcoplasmic reti...
|
T6936 |
PF-03814735
|
942487-16-3
|
98%
|
|
PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and...
|
T10592 |
BPR1K871
|
2443767-35-7
|
98%
|
|
BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values of 19...
|
T6193 |
Dovitinib Dilactic Acid
|
852433-84-2
|
98%
|
|
Dovitinib Dilactic Acid (Dovitinib (TKI-258) Dilactic Acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3...
|
T14055 |
5Z-7-Oxozeaenol
|
253863-19-3
|
98%
|
|
5Z-7-Oxozeaenol (FR148083) is a potent, irreversible and selective inhibitor of transforming growth factor (TGF)-β-activated kinase 1 with IC50 of 8.1 nM for TAK...
|
T11298 |
FLT3-IN-3
|
2229050-90-0
|
99.97%
|
|
FLT3-IN-3 is an effective FLT3 inhibitor, and the IC50s of FLT3 WT and FLT3 D835Y are 13 and 8 nM, respectively.
|
T1995 |
Fedratinib
|
936091-26-8
|
99.96%
|
|
Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
|
T2341 |
KW-2449
|
1000669-72-6
|
99.89%
|
|
KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 (IC50: 6.6 nM), modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R...
|
T4428 |
CCT241736
|
1402709-93-6
|
99.88%
|
|
CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3, ...
|
T2586 |
Cabozantinib
|
849217-68-1
|
99.88%
|
|
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Caboz...
|
T20743 |
TG-46
|
936091-15-5
|
99.87%
|
|
TG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.
|
T3068 |
AT9283
|
896466-04-9
|
99.87%
|
|
AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
|
T2638 |
Gandotinib
|
1229236-86-5
|
99.86%
|
|
LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM). The selectivity is higher 8- and 20-fold than JA...
|
T1777 |
Nintedanib
|
656247-17-5
|
99.85%
|
|
Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108...
|
T34656 |
SKLB 1028
|
1350544-93-2
|
99.85%
|
|
SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and con...
|
T3078 |
SGI-1776
|
1025065-69-3
|
99.84%
|
|
SGI-1776 (Pim-Kinase Inhibitor IX) has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.
|
T2640 |
Rebastinib
|
1020172-07-9
|
99.84%
|
|
DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HC...
|